"Company update this filing within every 3 year as each F-3 expires in 3 years unless there are any material development. Since the original filing of 2014, then 2017, AEZS has many material development such as FDA and EU approval on Macimorelin, then Novo/SBBP licensing deal, Torreya, etc. Please see the details in the timeline. It's just a standard filing to update just like shareholders' rights filing several months ago. You just cannot interpret in your own understanding..... facts..." sowie... "If this were a dilution, AEZS would've selected and checked the third option for additional shares public offering, but the AEZS selected the second option. This tells you that this is a just standard regular filing to update the info with development surrounding Macimorelin and others."
Die fachlich kompetenteren "da drüben " werten es als gängiges Procedere, die keine Verwässerung nach sich zieht, sehen es als weiteres Indiz für den nahenden Buyout (der statistisch gesehen am häufigsten MONTAG verkündet wird!) Warten wir weiter voller Hoffnung...
Einen schönen Sonntag für alle! |